EU
CRNX icon

Emory University’s Crinetics Pharmaceuticals CRNX Stock Holding History

Emory University’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-97,035
Closed -$2.21M – 48
2019
Q1 		$2.21M Buy
97,035
+11,091
+13% +$273K 1.55% 25
2018
Q4 		$2.58M Buy
+85,944
New +$2.42M 2.03% 5

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Emory University's CRNX Position: Q2 2019 in Review

Emory University sold out of Crinetics Pharmaceuticals (CRNX) in Q2 2019, closing a stake of 97,035 shares — an estimated $2.21M sold.

Emory University first reported a position in CRNX in Q4 2018 and held it in 2 quarters. The position peaked at $2.58M in Q4 2018. 63 funds tracked by Wall St. Rank hold CRNX as of Q2 2019.

  • Emory University reported no remaining Crinetics Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Emory University sold 97,035 Crinetics Pharmaceuticals shares in Q2 2019, an estimated $2.21M.
  • Emory University first reported a position in Crinetics Pharmaceuticals in Q4 2018 and held it in 2 quarters.
  • Emory University's Crinetics Pharmaceuticals position peaked at $2.58M in Q4 2018.
  • 63 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2019.

Based on Emory University's 13F filing for Q2 2019, filed 14 Aug 2019.